Plan to Lower Drug Pricing Could Be Underwhelming

Trump Official on Defensive as Critics Scoff at Drug Plan
– The Hill

Manatt’s Ian Spatz, a senior advisor with Manatt Health, spoke with The Hill for an article on President Trump’s chief health official and the administration’s plans to lower prescription drug prices.

The publication noted that Secretary of Health and Human Services Alex Azar is struggling to show that the administration is serious about taking on drug companies, as many analysts view the administration’s new plan as underwhelming.

Spatz explained that drug companies are “anticipating that there might be some immediate changes and when it became clear that nothing would happen [immediately],” there was an exhale. He explained that there are proposals in the administration’s plan that could harm the industry down the line, but much depends on the final details.

Read the article here



pursuant to New York DR 2-101(f)

© 2024 Manatt, Phelps & Phillips, LLP.

All rights reserved